Shares of Assembly Biosciences Inc. (ASMB) have surged more than 60% over the past month, driven by investor optimism ahead of multiple clinical data readouts expected in the coming months.
The company's lead drug candidate is ABI-4334, an orally bioavailable, next-generation capsid assembly modulator being developed for the treatment of chronic hepatitis B virus (HBV) infection - a disease that affects approximately 254 million people globally.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com